It was reported that a 20% reduction in the hepatic PA content and 35% reduction in the PA/LPA ratio was observed in NAFLD rats with expression of PNPLA3, which were associated with a 50% reduction in hepatic DG content and increased hepatic insulin sensitivity [29]. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.